HOME >> MEDICINE >> NEWS
Carbon monoxide from smoking helps keep arteries open following angioplasty

OAK BROOK, Ill.-In an unusual paradox, smoking cigarettes-a deadly habit that contributes to the development of peripheral artery disease-actually helps arteries stay open following a procedure to repair clogged blood vessels in the legs, according to a study in the June issue of Radiology. The study found that habitual to heavy smokers who continued to smoke after angioplasty had a lower rate of restenosis, or re-narrowing of the arteries, than nonsmokers.

As expected, the researchers who conducted the study at the University of Vienna, Austria, do not advocate smoking. But the findings suggest that increasing the level of carbon monoxide in the blood stream following angioplasty and stent placement within the lower limb arteries may help prevent restenosis.

"Smokers exhibit a higher blood concentration of carbon monoxide, a potent anti-inflammatory agent known to dilate blood vessels," said the study's lead author, Martin Schillinger, M.D., associate professor of internal medicine at the University of Vienna Medical School. "Carbon monoxide can inhibit the growth of smooth muscle cells within the artery wall, which is a key factor in the restenosis process."

In peripheral artery disease (PAD), a narrowing or blockage in the arteries causes an insufficient flow of oxygenated blood to the arms or legs. Interventional radiologists treat PAD with angioplasty, a minimally invasive procedure in which a balloon-tipped catheter-a thin, plastic tube-is threaded to the site of the blockage and inflated. Often the radiologist will place a wire mesh cylinder called a stent inside the artery to help prevent it from collapsing or becoming clogged again.

"Angioplasty and stent placement to repair obstructions in lower limb vessels have a high rate of restenosis," Dr. Schillinger said. "Up to 60 percent of patients who undergo endovascular interventions for PAD will experience restenosis and will need to repeat the treatment within a year." <
'"/>

Contact: Maureen Morley
mmorley@rsna.org
630-590-7754
Radiological Society of North America
25-May-2004


Page: 1 2

Related medicine news :

1. Carbon nanotubes yield a new class of biological sensors
2. Study: Carbon dioxide may find new use in producing medical implants
3. New first-aid method could prevent brain damage in patients exposed to carbon monoxide
4. Greater awareness of carbon monoxide poisoning needed among patients and doctors
5. NHS stop-smoking services are insufficient to deliver national smoking targets
6. Study suggests smoking while pregnant may increase chromosomal abnormalities in fetal cells
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. School-based smoking prevention programs ineffective
9. Parents who quit smoking may influence their offspring to quit as young adults
10. Inpatient smoking cessation counseling is associated with early differences in mortality
11. NHLBI study shows smoking cessation programs improve survival

Post Your Comments:
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
(Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
Cached News: